180 Life Sciences announces grants of two patents

180 Life Sciences (ATNF) announced two significant value enhancements to its existing, legacy intellectual property portfolio-reinforcing part of the Company’s strategy relating to continuing to build shareholder value through scientific innovation and patent protection for legacy IP assets. The Company has been granted and allowed protection in two discrete areas: Post Operative Cognitive Decline – The United States Patent and Trademark Office has granted U.S. Patent No. 12,325,744 B2, entitled “Methods and Agents for Preventing or Reducing Post-Operative Cognitive Decline.” This patent protects methods and therapeutic uses for reducing or preventing cognitive impairment in patients following a planned inflammatory trigger, such as surgery or chemotherapy. It also covers treatment of patients with cognitive disorders exacerbated by prior inflammatory exposure, strengthening 180’s IP in the neuroinflammation and surgical care space. Dupuytren’s Disease and Frozen Shoulder – The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders using an IL-33 antagonist. Upon payment of the requisite fee, a Canadian patent will be granted. This intellectual property supports 180’s clinical and translational legacy focus on novel anti-fibrotic therapies, with direct applicability to disorders such as Dupuytren’s Disease and Frozen Shoulder, both of which currently lack safe and effective non-surgical treatments. The USPTO patent granted in respect of Post Operative Cognitive Decline is owned by The Kennedy Trust, and licensed to 180, while the Canadian Notice of Allowance for a patent in respect of Dupuytren’s Disease and Frozen Shoulder is owned solely by the Company.